Chang, Bliss
Laffin, Luke J.
Sarraju, Ashish
Nissen, Steven E.
Article History
Accepted: 5 August 2024
First Online: 16 August 2024
Declarations
:
: Chang – No disclosures.Laffin – Dr. Laffin is a consultant and/or served on steering committees for Medtronic, Lilly, Mineralys Therapeutics, AstraZeneca, Idorsia, New Amsterdam, and Crispr Therapeutics; has received research funding from AstraZeneca; and has ownership interest in LucidAct Health and Gordy Health.Sarraju – Dr. Sarraju is the principal investigator of the TANDEM trial of obicetrapib. He receives no personal renumeration for this role as it paid to the C5 Research, the academic research organization of the Cleveland Clinic’s Heart, Vascular, and Thoracic Institute.Nissen – Dr. Nissen is the study chair for the TANDEM trial and a member of the Executive Committee supervising the PREVAIL Trial.
: This article does not contain any studies with human or animal subjects performed by any of the authors.